Therapy (IL-2)
"Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity."
Published in AIDS Weekly, December 4th, 1995
According to the authors' abstract of an article published in Blood, "Ten adult patients with human immunodeficiency virus (HIV)-associated malignancies (five with lymphoma and five with Kaposi's sarcoma) were treated with a daily subcutaneous injection of interleukin-2 (IL-2) for 90 consecutive days in a Phase I dose-escalation study. Seven patients had absolute CD4 counts below 200/mm3 at the time malignancy was diagnosed. Each lymphoma patient had obtained a complete or partial remission with standard chemotherapy before initiating IL-2. The daily dose of IL-2 did not change during the 90-day course of therapy. Seventeen courses of IL-2 therapy were completed at doses...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1995-12-04)
More Articles from AIDS Weekly
- Occupational Exposure (Prophylaxis)
PMPA Protects Monkeys Exposed to SIV - Conference Coverage (APHA)
HIV/TB Co-Infection Common in Puerto Rican IVDUs - Conference Coverage (APHA)
TB DOT Can Be Linked to HIV Prevention Services - HIV Gene Therapy
New Wave Protease Inhibitor Would Avoid Resistance - HIV Gene Therapy
Somatic Cell Gene Therapy of HIV Infection Explored - TB/HIV Coinfection
AIDS Patients with MDR-TB Can Be Successfully Treated - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
